1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSPARK for Innovations in Pediatrics: Proof-of-Concept Funding is sponsored by BARDA. Offers funding for 6-month, milestone-based projects that support the development, evaluation, and validation of innovative medical countermeasures for pediatric populations.
Get alerted about grants like this
Save a search for “BARDA” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
DRIVe | Partnering with DRIVe | Join us in advancing the next generation of health security solutions Join us in advancing the next generation of health security solutions DRIVe leverages flexible public-private partnering mechanisms to collaborate with a diverse spectrum of partners, including large and small companies, and academic and non-profit institutions.
DRIVe fosters a health security innovation ecosystem and supports the development, commercialization, and adoption of next-generation medical countermeasures.
Explore the opportunities below to find one that's right for Partnership Opportunities BARDA awards prizes through competitions focused on defined public health threats BARDA Accelerator Network VITAL: Therapeutics/Vaccines Hub $100 million for new broad-spectrum antiviral therapies.
ASPR and BARDA are proud to partner with VITAL - A BARDA Accelerator Network Hub - to support advancement of small molecule antivirals that strengthen national health security and improve preparedness for future public health threats. mission. Explore current opportunities accepting applications.
Broad Agency Announcement Seeks to support developing and characterizing of advanced in vitro platforms that replicate components of vital human tissues and the immune system and their interactions under homeostatic conditions.
Submissions that qualify for this funding shall preferably focus on engineering 3-D in vitro human microphysiological systems (MPS) representing various tissues with immune component(s) integrated on a single platform.
Rapid Response Partnership Vehicle RRPV: Assay development for Superior Understanding of Response and Efficacy (ASSURE) Seeks to develop innovative, multiplexed, high-throughput, scalable and sample sparing assays to more broadly assess protective immunity after pathogen exposure and/or vaccination, including measures of mucosal and cell-mediated immunity.
application submissions but BARDA Accelerator Network BioTools Innovator VANGUARD: Enabling BioTools Innovator VANGUARD: Proof-of-Concept Funding Funding ranging from $50K-$200K for 6-month, milestone-based projects that support the development, evaluation, and validation of enabling technologies that improve drug discovery and development; increase speed, capacity, portability and scalability; and improve clinical research and clinical care coordination.
BARDA Accelerator Network Paratus: Digital Health Hub Funding ranging from $50K-$200K for 4-week to 12-week, milestone-based projects that support the development, evaluation, and validation of digital health tools that enhance the nation's readiness to prepare and respond to health security threats. Uniquely, the program connects innovators with mission-aligned study sites to evaluate specific hypotheses for novel digital health MCMs.
BARDA Accelerator Network SPARK for Innovations in Pediatrics: Special SPARK for Innovations in Pediatrics: Proof-of-Concept Funding Funding ranging from $50k-$200K for 6-month, milestone-based projects that support the development, evaluation, and validation of innovative medical countermeasures that can enhance health security for pediatric populations.
BARDA Accelerator Network VITAL: Therapeutics/Vaccines Hub VITAL: Proof-of-Concept Funding Funding ranging from $50K-$200K for 6-month, milestone-based projects that support the development, evaluation and validation of therapeutic multi-use/platform solutions in alignment with BARDA's mission to promote health security.
*For opportunities without a deadline, proposals are accepted on an ongoing basis and reviewed based on BARDA priorities and availability of funds.
acceleration opportunities The BARDA Accelerator Network's Accelerator Programs offer cohort-based learning, including mentorship, entrepreneurship education, and access to technical and business/commercialization BARDA Accelerator Network BioTools Innovator VANGUARD: Enabling Technologies Hub BARDA Accelerator Network Paratus: Digital Health Hub BARDA Accelerator Network Pediatrics: Special Populations BARDA Accelerator Network VITAL: Therapeutics/Vaccines Hub Want to partner with BARDA?
This link goes to a non-USG site. This site may not have USG standard privacy control. Click OK to proceed in a separate browser window.
Based on current listing details, eligibility includes: Nonprofits, Universities, State/local governments, Private sector companies. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $50,000 - $200,000 Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.